FrancophonIA/ELRC3.0 huggingface dataset:
English: A feeling of weakness or feeling unwell, high blood pressure, irregular heart beat, fainting, chills or fever, indigestion, loss of appetite, constipation, bruising, bleeding, swelling (oedema), weight loss, muscle aches, painful joints, back pain, decreased or loss of feeling or sensation such as numbness, especially in the skin, abnormal feeling or sensation such as tingling and ‘pins and needles', sleeplessness, depression, confusion, nervousness, dry mouth, loss of memory, breathlessness, nosebleed, serious lung infection with fever, shortness of breath, cough, phlegm; hair loss, skin itching or discolouration, impotence, chest pain, reduction in blood platelets, which increases the risk of bleeding or bruising (thrombocytopenia), accumulation of fluid around the lungs or an increase in liver enzymes.
Croatian: Manje česte nuspojave: mogu se javiti u do 1 na 100 osoba Osjećaj slabosti ili osjećaj da Vam nije dobro, visoki krvni tlak, nepravilni otkucaji srca, nesvjestica, zimica ili vrućica, probavne smetnje, gubitak apetita, zatvor stolice, modrice, krvarenje, oticanje (edem), gubitak težine, bolovi u mišićima, bolni zglobovi, bol u leđima, smanjenje ili gubitak osjeta ili osjećaj kao što je utrnulost osobito kože, neprirodan osjećaj ili osjećaj bockanja i trnci, nesanica, depresija, smetenost, nervoza, suha usta, gubitak pamćenja, nedostatak zraka, krvarenje iz nosa, ozbiljna infekcija pluća s vrućicom, nedostatkom zraka, kašljanjem, sluzi, gubitak kose, svrbež kože ili promjena boje kože, impotencija, bol u prsnom košu, smanjenje broja krvnih pločica što povećava opasnost od krvarenja ili nastanka modrica (trombocitopenija), nakupljanje tekućine oko pluća ili porast vrijednosti jetrenih enzima.
English: Xagrid 0.5 mg hard capsules anagrelide
Croatian: NAZIV LIJEKA Xagrid 0,5 mg tvrde kapsule anagrelid
English: The no observed effect level (NOEL) for male dogs (0.3mg/kg/day) corresponds to 0.1, 0.1, and 1.6-fold the AUC in humans for anagrelide at 2mg/day, and the metabolites BCH24426 and RL603, respectively.
Croatian: Razina izloženosti pri kojoj nisu opaženi učinci (engl. no-observed-effect level, NOEL) za mužjake (0,3 mg/kg na dan) odgovara izloženosti 0,1; 0,1 i 1,6 puta većoj od AUC-a u ljudi za anagrelid u dozi od 2 mg na dan odnosno za metabolite BCH24426 i RL603.
English: Migraine Dysarthria Somnolence Abnormal coordination
Croatian: Migrena Dizartrija Somnolencija Poremećaj koordinacije
English: Atrial fibrillation Supraventricular tachycardia Arrhythmia Hypertension Syncope
Croatian: Ventrikularna tahikardija Kongestivno zatajenje srca Atrijska fibrilacija Supraventrikularna tahikardija Aritmija
English: At the NOEL dose (30mg/kg/day), the AUCs for anagrelide and the metabolites BCH24426 and RL603 were 425-, 31- and 13-fold higher than the AUC in humans administered an oral dose of anagrelide 2 mg/day, respectively.
Croatian: Pri NOEL dozi (30 mg/kg na dan), vrijednosti AUC-a za anagrelid i metabolite BCH24426 i RL603 bile su 425, odnosno 31 i 13 puta veće od AUC-a u ljudi nakon primjene peroralne doze anagrelida od 2 mg na dan.
English: Bleeding gums, weight gain, severe chest pain (angina pectoris), heart muscle disease, (signs include fatigue, chest pain and palpitations), enlarged heart, accumulation of fluid around the heart, loss of coordination, difficulty in speaking, dry skin, migraine, visual disturbances or double vision, ringing in the ears, dizziness on standing up (especially when getting up from a sitting or lying position), increased need to pass water at night, pain, ‘flu-like' symptoms, sleepiness, widening of blood vessels, inflammation of the large bowel (signs include: diarrhoea, usually with blood and mucus, stomach pain, fever), inflammation of the stomach (signs include: pain, nausea, vomiting), area of abnormal density in the lung, increased creatinine level in blood tests, which may be a sign of kidney problems.
Croatian: Rijetke nuspojave: mogu se javiti u do 1 na 1000 osoba Krvarenje iz desni, dobivanje na težini, teška bol u prsnom košu (angina pektoris), bolest srčanog mišića (znakovi uključuju umor, bol u prsnom košu i osjećaj lupanja srca), prošireno srce, nakupljanje tekućine oko srca, gubitak koordinacije, teškoće pri govoru, suha koža, migrena, poremećaj vida ili dvoslike, zvonjava u ušima, omaglica pri ustajanju (osobito pri ustajanju iz sjedećeg ili ležećeg položaja), povećana potreba za mokrenjem noću, bol, simptomi slični gripi, pospanost, širenje krvnih žila, upala debelog crijeva (znakovi uključuju proljev, obično uz prisutnost krvi i sluzi, bol u trbuhu, vrućicu), upala želuca (znakovi uključuju bol, mučninu, povraćanje), područje nenormalne gustoće u plućima, povišena razina kreatinina u pretragama krvi što može biti znak tegoba s bubrezima.
English: The NOEL (10mg/kg/day) to this effect was 143, 12 and 11-fold higher than the AUC in humans administered a dose of anagrelide 2 mg/day, and the metabolites BCH24426 and RL603, respectively.
Croatian: Kod tog učinka, vrijednost NOEL-a (10 mg/kg na dan) bila je 143, 12 i 11 puta veća od AUC-a u ljudi nakon primjene doze anagrelida od 2 mg na dan i metabolita BCH24426 i RL603.
English: At the NOEL dose (3mg/kg/day), the AUCs for anagrelide and the metabolites BCH24426 and RL603 were 14, 2 and 2-fold higher than the AUC in humans administered an oral dose of anagrelide 2mg/day.
Croatian: Pri NOEL dozi (3 mg/kg na dan), vrijednosti AUC-a za anagrelid i metabolite BCH24426 i RL603 bile su 14, 2 i 2 puta veće od AUC-a u ljudi nakon primjene peroralne doze anagrelida od 2 mg na dan.
English: One hard capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).
Croatian: Jedna kapsula sadrži 0,5 mg anagrelida (u obliku anagrelidklorida).
English: Dizziness, tiredness, rapid heart beat, irregular or strong heartbeat (palpitations), feeling sick (nausea), diarrhoea, stomach pain, wind, being sick (vomiting), reduction in red blood cell count (anaemia), fluid retention or rash.
Croatian: Česte nuspojave: mogu se javiti u do 1 na 10 osoba Omaglica, umor, brzi otkucaji srca, nepravilan ili snažan osjećaj lupanja srca (palpitacije), mučnina, proljev, bol u želucu, vjetrovi, povraćanje, sniženje broja crvenih krvnih stanica (slabokrvnost), zadržavanje tekućine ili osip.
English: Headache Dizziness Depression Amnesia
Croatian: Glavobolja Omaglica Depresija Amnezija Konfuzija Nesanica Parestezija Hipoestezija
English: Arthralgia Myalgia Back pain
Croatian: Artralgija Mialgija Bol u leđima
English: Chest pain Fever Chills Malaise Weakness
Croatian: Bol u prsnom košu Vrućica
English: Hypoaesthesia
Croatian: Anemija
English: Skin discoloration
Croatian: Promjena boje kože
English: Anaemia Pancytopenia Thrombocytopenia Haemorrhage
Croatian: Perikardijalni izljev
English: Frequency of adverse reactions
Croatian: Opći poremećaji i reakcije na mjestu primjene
English: Paraesthesia
Croatian: Epistaksa
English: Colitis Gastritis Gingival bleeding
Croatian: Hipertenzija Sinkopa
English: (Invented) name Strength Pharmaceutical form Route of administration
Croatian: blister (PVC/PCTFE/alu) asdf blister (bijeli PVC/PCTFE/alu)
English: Elderly people You can use this medicine if you are aged 75 years and over at the same dose as for other adults.
Croatian: Starije osobe Možete koristiti ovaj lijek ako imate 75 godina ili više pri istoj dozi kao i druge odrasle osobe.
English: Date of first authorisation: 28 September 2012 Date of latest renewal: 13 July 2017
Croatian: Datum posljednje obnove odobrenja: 13. srpnja 2017.
English: The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Croatian: Zahtjevi za podnošenje periodičkih izvješća o neškodljivosti za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim ažuriranim verzijamaobjavljenim na europskom internetskom portalu za lijekove.
English: Enurev Breezhaler can be used at the recommended dose in elderly patients (75 years of age and older) (see section 4.8).
Croatian: Enurev Breezhaler se može koristiti u preporučenoj dozi u starijih bolesnika (u dobi od 75 i više godina) (vidjeti dio 4.8).
English: • Enurev Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
Croatian: • Enurev Breezhaler kapsule moraju se uvijek čuvati u blister kartici i izvaditi tek neposredno prije primjene.
English: How to inhale Enurev Breezhaler - In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
Croatian: Kako inhalirati Enurev Breezhaler - U ovom pakiranju naći ćete inhalator i kapsule (u blisterima) koji sadrže lijek kao prašak inhalata.
English: Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Croatian: Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka, putem nacionalnog sustava prijave nuspojava: navedenog u Dodatku V.
English: Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Enurev Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.
Croatian: Bolesnike treba obavijestiti o znakovima i simptomima akutnog glaukoma uskog kuta i uputiti ih da prestanu koristiti Enurev Breezhaler te da se odmah obrate svom liječniku ako se pojavi bilo koji od tih znakova i simptoma.
English: The capsules must be administered only using the Enurev Breezhaler inhaler (see section 6.6).
Croatian: Kapsule se moraju primjenjivati isključivo korištenjem Enurev Breezhaler inhalatora (vidjeti dio 6.6).
English: There is no relevant use of Enurev Breezhaler in the paediatric population (under 18 years) in the indication COPD.
Croatian: Nema relevantne primjene Enurev Breezhalera u pedijatrijskoj populaciji (mlađih od 18 godina) u indikaciji KOPB-a.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Enurev Breezhaler in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Enurev Breezhaler u svim podskupinama pedijatrijske populacije u KOPB-u (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: The recommended dose is the inhalation of the content of one capsule once daily using the Enurev Breezhaler inhaler.
Croatian: Preporučena doza je inhalacija sadržaja jedne kapsule jedanput na dan korištenjem Enurev Breezhaler inhalatora.
English: In clinical studies with Enurev Breezhaler, paradoxical bronchospasm was not observed.
Croatian: U kliničkim ispitivanjima sa Enurev Breezhalerom nije bio uočen paradoksalni bronhospazam.
English: - When you start a new pack, use the new Enurev Breezhaler inhaler that is supplied in the pack.
Croatian: - Kada otvorite novo pakiranje, upotrijebite novi Enurev Breezhaler inhalator koji je priložen u pakiranju.
English: Following oral inhalation using the Enurev Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes post dose.
Croatian: Nakon oralne inhalacije korištenjem Enurev Breezhaler inhalatora, glikopironij se brzo apsorbirao i dosegnuo vršne razine u plazmi 5 minuta nakon doze.
English: What Enurev Breezhaler is and what it is used for What you need to know before you use Enurev Breezhaler How to use Enurev Breezhaler Possible side effects
Croatian: Što je Enurev Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Enurev Breezhaler Kako primjenjivati Enurev Breezhaler Moguće nuspojave
English: During treatment with Enurev Breezhaler, stop taking this medicine and tell your doctor immediately: - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Enurev Breezhaler (signs of bronchospasm).
Croatian: Tijekom liječenja Enurev Breezhalerom prestanite primjenjivati ovaj lijek i odmah se obratite liječniku: - ako osjetite stezanje u prsnom košu, kašljanje, piskanje ili nedostatak zraka odmah nakon primjene Enurev Breezhalera (znakovi bronhospazma).
English: The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the prolonged terminal elimination half-life of glycopyrronium after inhalation via the Enurev Breezhaler inhaler in contrast to the half life after intravenous administration (see section 5.2).
Croatian: Dugo trajanje djelovanja djelomično se može pripisati održanim koncentracijama djelatne tvari u plućima što se odražava produljenim terminalnim poluvijekom eliminacije glikopironija nakon inhalacije putem Enurev Breezhaler inhalatora za razliku od poluvijeka nakon intravenske primjene (vidjeti dio 5.2).
English: Enurev Breezhaler once daily has also shown a statistically significant effect on health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ).
Croatian: Enurev Breezhaler jedanput na dan također je pokazao statistički značajan učinak na kvalitetu života povezanu sa zdravljem mjerenu korištenjem „St. George“ respiratornog upitnika (eng.
English: No change in mean heart rate or QTc interval was observed with Enurev Breezhaler in doses up to 176 micrograms in COPD patients.
Croatian: Nije bila uočena nikakva promjena u srednjoj srčanoj frekvenciji ili QTc intervalu sa Enurev Breezhalerom u dozama do 176 mikrograma u bolesnika s KOPB-om.
English: Enurev Breezhaler should be used with caution in these patient groups.
Croatian: Enurev Breezhaler treba oprezno koristiti u tih skupina bolesnika.
English: Enurev Breezhaler 44 micrograms once daily provided consistently statistically significant improvement in lung function (forced expiratory volume in one second, FEV1, forced vital capacity, FVC, and inspiratory capacity, IC) in a number of clinical studies.
Croatian: Enurev Breezhaler 44 mikrograma jedanput na dan omogućio je dosljedno statistički značajno poboljšanje plućne funkcije (forsirani izdisajni volumen u jednoj sekundi, FEV1, forsirani vitalni kapacitet, FVC, i inspiratorni kapacitet, IC) u više kliničkih ispitivanja.
English: Acute intoxication by inadvertent oral ingestion of Enurev Breezhaler capsules is unlikely due to the low oral bioavailability (about 5%).
Croatian: Akutna intoksikacija slučajnim oralnim unosom kapsula Enurev Breezhaler malo je vjerojatna zbog niske oralne bioraspoloživosti (oko 5%).
English: If you use more Enurev Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit.
Croatian: Ako ste inhalirali previše ovog lijeka ili ako netko zabunom uzme Vaše kapsule, morate odmah obavijestiti svog liječnika ili otići u najbližu hitnu pomoć.
English: Although no formal drug interaction studies have been performed, Enurev Breezhaler has been used concomitantly with other medicinal products commonly used in the treatment of COPD without clinical evidence of drug interactions.
Croatian: Iako nisu provedena formalna ispitivanja interakcija među lijekovima, Enurev Breehaler je istodobno primjenjivan s drugim lijekovima koji se često primjenjuju u liječenju KOPB-a bez kliničkog dokaza o interakcijama među lijekovima.
English: Talk to your doctor before using Enurev Breezhaler, if any of the following applies to you: - you have kidney problems.
Croatian: Obratite se svom liječniku prije nego primijenite Enurev Breezhaler, ako se bilo što od navedenoga u nastavku odnosi na Vas: - ako imate tegobe s bubrezima.
English: Enurev Breezhaler 44 micrograms once daily can be safely used in all age and body weight groups.
Croatian: Enurev Breezhaler 44 mikrograma jedanput na dan može se sigurno primjenjivati u svim dobnim skupinama i skupinama prema tjelesnoj težini.
English: There are no data from the use of Enurev Breezhaler in pregnant women.
Croatian: Nema podataka o primjeni Enurev Breezhaler u trudnica.
English: This includes medicines similar to Enurev Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).
Croatian: To uključuje lijekove koji su slični Enurev Breezhaleru i koriste se za Vašu plućnu bolest, kao što su ipratropij, oksitropij ili tiotropij (takozvani antikolinergici).
English: In a 3-week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Enurev Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards.
Croatian: U 3-tjednom ispitivanju gdje je tolerancija napora bila ispitivana pomoću biciklergometra pri submaksimalnom (80%) opterećenju (submaksimalni test tolerancije napora), Enurev Breezhaler, primijenjen ujutro, smanjio je dinamičku hiperinflaciju i poboljšao duljinu vremena tijekom kojeg se mogao održavati napor od prve doze nadalje.
English: The co-administration of Enurev Breezhaler with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Croatian: Istodobna primjena Enurev Breezhalera s drugim lijekovima koji sadrže antikolinergike nije bila proučavana pa se stoga ne preporučuje.
English: Concomitant administration of glycopyrronium and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Croatian: Istodobna primjena glikopironijai oralno inhaliranog indakaterola, beta2-adrenergičkog agonista, u stanju dinamičke ravnoteže obje djelatne tvari nije utjecala na farmakokinetiku ni jednog ni drugog lijeka.
English: The absolute bioavailability of glycopyrromium inhaled via Enurev Breezhaler was estimated to be about 45% of the delivered dose.
Croatian: Procijenjeno je da je apsolutna bioraspoloživost glikopironija inhaliranog preko Enurev Breezhalera oko 45% isporučene doze.
English: Enurev Breezhaler is recommended to be administered, at the same time of the day each day.
Croatian: Preporučuje se da se Enurev Breezhaler primjenjuje u isto vrijeme svakoga dana.
English: No specific side effects have been reported when Enurev Breezhaler has been used together with other medicines used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Croatian: Nisu prijavljene posebne nuspojave kada se Enurev Breezhaler primjenjivao istodobno s drugim lijekovima koji se primjenjuju za liječenje KOPB-a kao što su inhalatori za olakšavanje tegoba (npr. salbutamol), metilksantini (npr. teofilin) i/ili oralni i inhalacijski steroidi (npr. prednizolon).
English: Please read the full Instructions for Use before using the Enurev Breezhaler.
Croatian: Pročitajte u cijelosti Upute za primjenu prije korištenja Enurev Breezhalera.
English: 6 or 10 Seebri Breezhaler capsules to be used in the inhaler
Croatian: 6 ili 10 Enurev Breezhaler kapsula za korištenje u inhalatoru
English: In COPD patients with mild and moderate renal impairment (estimated glomerular filtration rate, eGFR ≥30 ml/min/1.73 m2) Enurev Breezhaler can be used at the recommended dose.
Croatian: U bolesnika s KOPB-om i s blagim i umjerenim oštećenjem bubrega (procijenjena glomerularna filtracija, eGFR ≥30 ml/min/1,73 m2) Enurev Breezhaler može se koristiti pri preporučenoj dozi.
English: Enurev Breezhaler is a once-daily, long-term maintenance treatment and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.
Croatian: Enurev Breezhaler je dugoročna terapija održavanja koja se primjenjuje jedanput na dan i nije indiciran za inicijalno liječenje akutnih epizoda bronhospazama, tj. za hitno ublažavanje simptoma.
English: In the pooled 6-month database the frequency of dry mouth was 2.2% versus 1.1%, of insomnia 1.0% versus 0.8%, and of gastroenteritis 1.4% versus 0.9%, for Enurev Breezhaler and placebo respectively.
Croatian: U bazi objedinjenih 6-mjesečnih podataka učestalost suhih usta bila je 2,2% naspram 1,1%, nesanice 1,0% naspram 0,8%, te gastroenteritisa 1,4% naspram 0,9% za Enurev Breezhaler odnosno placebo.
English: Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Croatian: Enurev Breezhaler je indiciran kao bronhodilatacijska terapija održavanja za ublažavanje simptoma u odraslih bolesnika s kroničnom opstruktivnom plućnom bolešću (KOPB).
English: After three weeks of treatment the improvement in inspiratory capacity with Enurev Breezhaler was similar to the first day (200 ml), exercise endurance time however had increased by 89 seconds (an increase of 21%) compared to placebo.
Croatian: Nakon tri tjedna liječenja poboljšanje u inspiratornom kapacitetu sa Enurev Breezhalerom bilo je slično onome za prvi dan (200 ml), vrijeme izdržavanja napora se, međutim, povećalo za 89 sekundi (povećanje od 21%) u usporedbi s placebom.
English: What Enurev Breezhaler contains - The active substance is glycopyrronium bromide.
Croatian: Što Enurev Breezhaler sadrži - Djelatna tvar je glikopironijev bromid.
English: The pooled analysis also showed fewer patients treated with Enurev Breezhaler than with placebo experienced an exacerbation requiring hospitalisation (1.7% versus 4.2%, p=0.003).
Croatian: Objedinjena analiza također je pokazala da je manje bolesnika liječenih Enurev Breezhalerom nego onih koji su primali placebo doživjelo egzacerbaciju koja je zahtijevala hospitalizaciju (1,7% u usporedbi s 4,2%, p=0,003).
English: When to inhale Enurev Breezhaler Use this medicine at the same time each day.
Croatian: Kada inhalirati Enurev Breezhaler Primjenjujte ovaj lijek u isto vrijeme svaki dan.
English: Peak plasma levels and total systemic exposure following intravenous administration of 150 micrograms glycopyrronium bromide (equivalent to 120 micrograms glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total exposure at steady-state achieved with the recommended dose (44 micrograms once daily) of Enurev Breezhaler and were well tolerated.
Croatian: Vršne razine u plazmi i ukupna sistemska izloženost nakon primjene u venu 150 mikrograma glikopironijevog bromida (što je ekvivalentno 120 mikrograma glikopironija) u zdravih dobrovoljaca bile su oko 50 odnosno 6 puta više od vršne i ukupne izloženosti u stanju dinamičke ravnoteže postignute uz preporučenu dozu (44 mikrograma jedanput na dan) Enurev Breezhalera i dobro su se podnosile.
English: Enurev Breezhaler contains lactose
Croatian: Enurev Breezhaler sadrži laktozu
English: Enurev Breezhaler is used as a maintenance treatment for your COPD.
Croatian: Enurev Breezhaler se koristi kao terapija održavanja za Vaš KOPB.
English: • Do not use the Enurev Breezhaler inhaler to take any other capsule medicine.
Croatian: • Nemojte koristiti Enurev Breezhaler inhalator za uzimanje kapsula bilo kojeg drugog lijeka.
English: What Enurev Breezhaler looks like and contents of the pack Enurev Breeyhaler 44 micrograms inhalation powder, hard capsules are transparent and orange and contain a white powder.
Croatian: Kako Enurev Breezhaler izgleda i sadržaj pakiranja Enurev Breezhaler 44 mikrograma prašak inhalata, tvrde kapsule su prozirne i narančaste te sadrže bijeli prašak.